1 research outputs found
ΠΠ·Π°ΠΈΠΌΠΎΡΠ²ΡΠ·Ρ Π½Π΅ΠΊΠΎΡΠΎΡΡΡ ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠΎΠ² ΠΌΡΠΊΠΎΠ·Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΈΠΌΠΌΡΠ½ΠΈΡΠ΅ΡΠ° ΠΏΠΎΠ»ΠΎΡΡΠΈ ΡΡΠ° Ρ ΡΡΠΎΠ²Π½Π΅ΠΌ Π²ΠΈΡΠ°ΠΌΠΈΠ½Π° D Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΌΠ½ΠΎΠΆΠ΅ΡΡΠ²Π΅Π½Π½ΡΠΌ ΠΊΠ°ΡΠΈΠ΅ΡΠΎΠΌ
Aim. To determine the saliva level of immunoregulatory proteins in patients with rampant caries and 25-hydroxyvitamin D (25(OH)D) deficiency and evaluate the association of their concentration with 25(OH)D plasma level.Materials and methods. The study was performed in two groups. The experimental group included 15 patients aged 20β22 years with rampant caries and the 25(OH)D plasma level of < 20 ng / ml. The control group encompassed 15 healthy age-matched volunteers with the 25(OH)D plasma level of 20β100 ng / ml. The concentrations of B7.2 (CD86), free active TGF-Ξ²1, CTLA-4, PD-1, Tim-3, LAG-3, IGFBP-4, and ICAM-1 were assessed using flow cytometry. The levels of LL-37 and secretory immunoglobulin A (sIgA) were measured using ELISA. The Spearmanβs rank correlation coefficient was used to reveal a correlation between the indicated proteins and the 25(OH)D plasma level.Results. A decrease in B7.2 (CD86), PD-1, Tim-3, sIgA, and LL-37 and elevation of IGFBP-4 and ICAM-1 saliva levels were detected in patients with rampant caries and 25-hydroxyvitamin D deficiency. A positive Spearmanβs rank correlation coefficient was revealed between plasma 25(OH)D and saliva levels of free active TGF-Ξ²1, CTLA4, B7.2 (CD86), LL-37, and sIgA. A negative correlation was revealed between 25(OH)Dand ICAM-1.Conclusion. 25(OH)D deficiency in patients with rampant caries is associated with decreased levels of B7.2 (CD86), PD-1, Tim-3, sIgA, and LL-37 and elevated levels of IGFBP-4 and ICAM-1 in the saliva.Β Π¦Π΅Π»Ρ β ΠΎΡΠ΅Π½ΠΈΡΡ ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅Π³ΡΠ»ΡΡΠΎΡΠ½ΡΡ
ΠΌΠΎΠ»Π΅ΠΊΡΠ» Π² ΡΠ»ΡΠ½Π΅ Ρ Π»ΠΈΡ Ρ ΠΌΠ½ΠΎΠΆΠ΅ΡΡΠ²Π΅Π½Π½ΡΠΌ ΠΊΠ°ΡΠΈΠ΅ΡΠΎΠΌ ΠΈ Π΄Π΅ΡΠΈΡΠΈΡΠΎΠΌ 25(OH)D3 ΠΈ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΠΈΡΡ Π²Π·Π°ΠΈΠΌΠΎΡΠ²ΡΠ·ΠΈ ΠΈΡ
Π²Π΅Π»ΠΈΡΠΈΠ½ Ρ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠ΅ΠΉ 25(OH)D3 Π² ΠΊΡΠΎΠ²ΠΈ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Ρ Π΄Π²Π΅ Π³ΡΡΠΏΠΏΡ Π»ΠΈΡ Π² Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ 20β22 Π»Π΅Ρ. Π ΠΎΠ΄Π½Ρ Π²ΠΊΠ»ΡΡΠ΅Π½Ρ 15 ΡΠ΅Π»ΠΎΠ²Π΅ΠΊ Ρ ΠΊΠ°ΡΠΈΠ΅ΡΠΎΠΌ ΠΈ ΡΡΠΎΠ²Π½Π΅ΠΌ 25(OH)D3 ΠΌΠ΅Π½Π΅Π΅ 20 Π½Π³/ΠΌΠ», Π² Π΄ΡΡΠ³ΡΡ (ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΡΡ) β 15 Π·Π΄ΠΎΡΠΎΠ²ΡΡ
ΡΠ΅Π»ΠΎΠ²Π΅ΠΊ Ρ ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅ΠΌ 25(OH)D3 30β100 Π½Π³/ΠΌΠ». Π ΡΠΎΡΠΎΠ²ΠΎΠΉ ΠΆΠΈΠ΄ΠΊΠΎΡΡΠΈ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Ρ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ ΡΠ°ΡΡΠ²ΠΎΡΠΈΠΌΡΡ
ΡΠΎΡΠΌ ΠΌΠΎΠ»Π΅ΠΊΡΠ» B7.2 (CD86), Free Active TGF-b1, CTLA-4, PD-1, Tim-3, LAG-3, IGFBP-4, ICAM-1 ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΏΡΠΎΡΠΎΡΠ½ΠΎΠΉ ΡΠΈΡΠΎΡΠ»ΡΠΎΠΌΠ΅ΡΡΠΈΠΈ, ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ ΠΊΠ°ΡΠ΅Π»ΠΈΡΠΈΠ΄ΠΈΠ½Π° LL-37, ΡΠ΅ΠΊΡΠ΅ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΠΈΠΌΠΌΡΠ½ΠΎΠ³Π»ΠΎΠ±ΡΠ»ΠΈΠ½Π° A (IgA) ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠΌΠ΅Π½ΡΠ½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π°. ΠΠ΅ΠΆΠ΄Ρ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ΅ΠΌΡΠΌΠΈ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΠΌΠΈ ΡΠ°ΡΡΡΠΈΡΠ°Π½ ΠΊΡΠΈΡΠ΅ΡΠΈΠΉ ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΠΈ Π‘ΠΏΠΈΡΠΌΠ΅Π½Π°.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π£ Π»ΠΈΡ Ρ ΠΊΠ°ΡΠΈΠ΅ΡΠΎΠΌ ΠΈ Π΄Π΅ΡΠΈΡΠΈΡΠΎΠΌ Π²ΠΈΡΠ°ΠΌΠΈΠ½Π° D Π²ΡΡΠ²Π»Π΅Π½ΠΎ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠΉ Free Active TGF-b1, B7.2 (CD86), PD-1, Tim-3, sIgA, ΠΊΠ°ΡΠ΅Π»ΠΈΡΠΈΠ΄ΠΈΠ½Π° LL-37 ΠΈ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠ΅ ΡΡΠΎΠ²Π½Ρ IGFBP-4 ΠΈ ICAM-1 Π² ΡΠ»ΡΠ½Π΅. ΠΠ±Π½Π°ΡΡΠΆΠ΅Π½ΠΎ Π½Π°Π»ΠΈΡΠΈΠ΅ ΠΏΡΡΠΌΡΡ
ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΠΎΠ½Π½ΡΡ
ΡΠ²ΡΠ·Π΅ΠΉ ΠΌΠ΅ΠΆΠ΄Ρ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎΠΌ 25(OH)D3 Π² ΠΊΡΠΎΠ²ΠΈ, Ρ ΠΎΠ΄Π½ΠΎΠΉ ΡΡΠΎΡΠΎΠ½Ρ, ΠΈ Π·Π½Π°ΡΠ΅Π½ΠΈΡΠΌΠΈ Free Active TGF-b1, CTLA-4, Π7.2 (CD86), ΡΠ΅ΠΊΡΠ΅ΡΠΎΡΠ½ΠΎΠ³ΠΎ IgA, ΠΏΠ΅ΠΏΡΠΈΠ΄Π° LL-37 β Ρ Π΄ΡΡΠ³ΠΎΠΉ. ΠΠ°ΡΠΈΠΊΡΠΈΡΠΎΠ²Π°Π½Π° ΠΎΡΡΠΈΡΠ°ΡΠ΅Π»ΡΠ½Π°Ρ Π²Π·Π°ΠΈΠΌΠΎΡΠ²ΡΠ·Ρ ΠΌΠ΅ΠΆΠ΄Ρ Π²Π΅Π»ΠΈΡΠΈΠ½Π°ΠΌΠΈ 25(OH)D3 ΠΈ ICAM-1.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠ° ΡΠΎΠ½Π΅ Π΄Π΅ΡΠΈΡΠΈΡΠ° Π²ΠΈΡΠ°ΠΌΠΈΠ½Π° D ΠΏΡΠΈ ΠΌΠ½ΠΎΠΆΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠΌ ΠΊΠ°ΡΠΈΠ΅ΡΠ΅ Π² ΡΠΎΡΠΎΠ²ΠΎΠΉ ΠΆΠΈΠ΄ΠΊΠΎΡΡΠΈ ΡΠ΅Π³ΠΈΡΡΡΠΈΡΡΡΡΡΡ Π½ΠΈΠ·ΠΊΠΈΠ΅ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ Free Active TGF-b1, B7.2 (CD86), PD-1, Tim-3, ΡΠ΅ΠΊΡΠ΅ΡΠΎΡΠ½ΠΎΠ³ΠΎ IgA, ΠΊΠ°ΡΠ΅Π»ΠΈΡΠΈΠ΄ΠΈΠ½Π° LL-37 ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΠΊΠΎΠ½ΡΡΠΎΠ»Π΅ΠΌ, Π½ΠΎ ΡΠ²Π΅Π»ΠΈΡΠ΅Π½Ρ Π·Π½Π°ΡΠ΅Π½ΠΈΡ IGFBP-4 ΠΈ ICAM-1.